glra1 Antibody

What is GLRA1 and what is its function in the nervous system?

GLRA1 (Glycine Receptor Alpha 1) is a subunit of pentameric inhibitory glycine receptors that mediate postsynaptic inhibition in the central nervous system. These receptors form chloride ion channels that are activated by extracellular glycine, as well as by taurine and beta-alanine, though with different potencies. GLRA1-containing receptors play a crucial role in downregulating neuronal excitability and contribute significantly to inhibitory postsynaptic currents . These receptors are widely distributed throughout the CNS, with particularly high expression in the hippocampus, spinal cord, and brainstem . At the molecular level, GLRA1 is part of the cys-loop family of ligand-gated ion channels, with the functional receptor typically being a heteropentamer composed of alpha and beta subunits, though homopentameric receptors consisting only of alpha subunits can also form .

What types of GLRA1 antibodies are available for research purposes and how are they generated?

Several types of GLRA1 antibodies are available for research, including:

• Polyclonal antibodies: Generated by immunizing animals (typically rabbits or goats) with synthetic peptides corresponding to specific regions of human GLRA1. For example, some commercial antibodies are raised against peptides from the internal region of GLRA1 (amino acids 141-155) or from the second intracellular loop (amino acids 350-362) .

• Monoclonal antibodies: Generated through hybridoma technology, including clones like 2E6, 4D9, and 7F8E2, each recognizing specific epitopes within the GLRA1 protein .

• Isoform-specific antibodies: Some antibodies specifically target the alpha 1 and alpha 2 subunits of glycine receptors, such as the antibody mentioned in search result , which recognizes the ~48 kDa alpha 1 and alpha 2 subunits but does not bind to other glycine receptor subunits.

The most common generation method involves synthesizing peptides corresponding to specific regions of GLRA1, conjugating them to carrier proteins, immunizing animals, and then purifying the antibodies through affinity chromatography using methods such as SulfoLink™ Coupling Resin .

How should GLRA1 antibodies be stored and handled to maintain their activity?

For optimal stability and performance of GLRA1 antibodies:

After reconstitution (if lyophilized), some antibodies should be reconstituted with 100 µL PBS as noted in search result . For shipping, most GLRA1 antibodies are transported on blue ice to maintain stability . It's important to note that sodium azide, commonly used as a preservative in antibody solutions, is toxic and should be handled with care.

What are the optimal dilutions and applications for GLRA1 antibodies in different experimental techniques?

Based on the search results, the recommended dilutions and applications for GLRA1 antibodies vary by technique:

For live cell staining protocols, cells are typically incubated with the primary antibody (1:25) applied into the cell culture medium for 1 hour at 4°C before fixation . For immunohistochemical staining of tissue sections, indirect single and double immunofluorescence staining can be performed on cryostat sections of fresh frozen tissue, with human sera typically used at dilutions of 1:200 to 1:800 and commercial antibodies at 1:500 .

How can researchers verify the specificity of GLRA1 antibodies and eliminate false positive results?

To verify GLRA1 antibody specificity and eliminate false positives, researchers should implement several control approaches:

• Peptide blocking/preadsorption: Preincubate the antibody with the immunizing peptide before application. If staining is specific, the peptide should block antibody binding, as demonstrated in several studies where immunolabeling was blocked by preadsorption of antibody with the peptide immunogen .

• Genetic controls: Use tissues or cells from GLRA1 knockout models or those expressing mutant forms of GLRA1 (e.g., GLRA1^spdot/spdot mice) as negative controls .

• Cross-adsorption against related proteins: Pre-adsorb sera against cells expressing different glycine receptor subunits (GlyRα1, GlyRα2, GlyRα3) to test for cross-reactivity .

• Multiple antibody validation: Use different antibodies targeting different epitopes of GLRA1 and compare staining patterns .

• Western blot validation: Confirm the antibody detects a band of the expected molecular weight (~48-53 kDa for GLRA1) .

• Positive and negative tissue controls: Include tissues known to express high levels of GLRA1 (spinal cord, brainstem) and tissues with low expression as controls .

Search result describes a comprehensive approach where four sera were pre-adsorbed against HEK cells expressing GlyRα1, GlyRα2, Glyα3 or untransfected HEK cells, or with recombinant GAD overnight at 4°C before applying to rat brain sections to confirm specificity.

What protocols are most effective for detecting GLRA1 in different subcellular compartments?

For effective detection of GLRA1 in different subcellular compartments, researchers can employ several specialized protocols:

• Surface GLRA1 detection:

  • Biotinylation assay: Cell surface proteins are labeled with biotin, isolated using streptavidin beads, and analyzed by Western blot. This protocol has been successfully applied with transfected COS7 cells .

  • Live cell immunolabeling: Apply antibodies to live cells at 4°C (to prevent internalization) before fixation, as described in several studies .

• Intracellular GLRA1 detection:

  • Fixed and permeabilized cells: Fix cells with paraformaldehyde (typically 4%) and permeabilize with 0.1-0.3% Triton X-100 before antibody application .

  • Co-staining with compartment markers: Use antibodies against organelle markers (ER – calnexin; ERGIC – ERGic53; cis-Golgi – GM130) to identify GLRA1 location .

• Trafficking analysis:

  • Temperature shift experiments: Incubate antibody-labeled cells at either 4°C (to prevent internalization) or 37°C (to permit trafficking) for varying times to track receptor movement .

  • Endosomal co-localization: Co-stain with markers for late endosomes to identify internalized receptors .

  • Glycosylation analysis: Use glycosidases (Endo H and PNGase F) to determine the glycosylation status of GLRA1, which indicates its progression through the secretory pathway .

Figure 4 from search result illustrates a comprehensive approach for analyzing GLRA1 trafficking defects, showing compartmental analysis of transfected cells with labeling for different cellular compartments.

How can GLRA1 antibodies be used to study neurological disorders like hereditary hyperekplexia and stiff-person syndrome?

GLRA1 antibodies are powerful tools for investigating neurological disorders related to glycine receptor dysfunction:

• Genetic mutation analysis: GLRA1 antibodies can detect altered expression, trafficking, or localization of mutant GLRA1 proteins. Studies have effectively used these antibodies to characterize trafficking defects in hereditary hyperekplexia-associated GLRA1 mutations, as shown in search result which visualized the cellular accumulation of mutant GlyR α1 D70N primarily in the ER.

• Autoimmune disorder investigation: In disorders like stiff-person syndrome (SPS) and progressive encephalomyelitis with rigidity and myoclonus (PERM), GLRA1 antibodies help identify autoantibodies targeting glycine receptors. Cell-based assays using HEK293 cells transfected to express homo-pentamers of GlyRα1 tagged with enhanced green fluorescent protein allow detection of patient autoantibodies binding to GlyRs .

• Receptor internalization studies: GLRA1 antibodies enable quantification of receptor internalization mechanisms in autoimmune conditions. For instance, research has shown that in some patients, GlyR antibodies cause internalization of receptors, which can be visualized using GlyR-EGFP transfected cells and analyzed with ImageJ software .

• Pathophysiological mechanism elucidation: By combining GLRA1 antibodies with electrophysiological techniques, researchers can correlate receptor expression with functional deficits. Search result demonstrates how antibodies against GlyRβ were used to show that some patients' autoantibodies impair glycine efficacy rather than potency, providing insights into disease mechanisms.

• Treatment response monitoring: GLRA1 antibodies can be used to monitor changes in receptor expression or antibody levels following immunotherapy in autoimmune disorders, helping assess treatment efficacy.

The study mentioned in search result identified 52 antibody-positive patients with glycine receptor antibodies and tracked their clinical features, investigations, and immunotherapy responses over 2-7 years, showing marked improvement with immunotherapies in most cases.

What techniques are available for studying GLRA1 trafficking defects in neurological disease models?

Multiple sophisticated techniques can be employed to study GLRA1 trafficking defects:

• Live cell imaging with fluorescently tagged receptors:

  • GlyR-EGFP fusion proteins allow real-time visualization of receptor movement

  • Combined with cyclohexamide treatment to prevent new protein synthesis, this technique enables selective tracking of existing surface receptors

• Compartmental colocalization analysis:

  • Co-staining with markers for ER (calnexin), ERGIC (ERGic53), and cis-Golgi (GM130)

  • Allows precise localization of where mutant receptors accumulate in the secretory pathway

  • Search result illustrates this approach with GlyR α1 D70N mutant analysis

• Glycosylation status analysis:

  • Treatment with specific glycosidases:

    • Endo H (cleaves high mannose glycans in ER)

    • PNGase F (removes all N-linked glycans)

  • Differential sensitivity to these enzymes indicates progression through the secretory pathway

  • As shown in search result , this technique reveals whether receptors have exited the ER

• Quantitative surface expression assays:

  • Biotinylation of surface proteins followed by streptavidin pull-down

  • Comparison between wild-type and mutant receptors quantifies trafficking deficits

  • Surface expression normalized to a housekeeping protein (e.g., pan-cadherin)

• Pulse-chase experiments:

  • Metabolic labeling with radioactive amino acids

  • Tracking protein maturation over time

  • Reveals kinetics of receptor processing and surface delivery

• Mutagenesis approaches:

  • Overlap extension PCR strategies to create domain exchanges or specific mutations

  • Allows structure-function analysis of trafficking motifs

  • As described in search result , this approach has been used to study the impact of specific mutations on GLRA1 trafficking

These techniques have successfully identified that many recessive mutations in GLRA1 cause trafficking defects to the cellular surface, with protein accumulation most pronounced in the ER, as demonstrated in Figure 4 of search result .

How can GLRA1 antibodies be used in conjunction with electrophysiology to correlate protein expression with functional deficits?

Combining GLRA1 antibody techniques with electrophysiology provides powerful insights into structure-function relationships:

• Paired immunocytochemistry and patch-clamp recordings:

  • Transfect cells with wild-type or mutant GLRA1

  • Perform whole-cell patch-clamp to measure glycine-evoked currents

  • Fix and immunolabel the same cells to quantify surface expression

  • Correlate current amplitude with receptor density

  • Research results and demonstrate this approach, showing how antibody binding to GlyRβ impaired glycine efficacy

• Surface biotinylation coupled with electrophysiology:

  • Record from a population of cells

  • Perform surface biotinylation assay on the same population

  • Correlate average current densities with surface expression levels

  • This approach can determine if functional deficits are due to trafficking issues or altered channel properties

• Real-time visualization during recording:

  • Use GFP-tagged GLRA1 constructs to visualize receptors

  • Simultaneously record currents with patch-clamp

  • Track receptor clustering or internalization during agonist application

  • Can be combined with antibody-mediated crosslinking to study clustering mechanisms

• Antibody modulation during recording:

  • Apply GLRA1 antibodies during patch-clamp recording

  • Observe acute effects on channel function

  • Particularly useful for studying patient-derived autoantibodies

  • Search result used this approach to show that binding of GlyRβ autoantibodies from two patients to its target impaired glycine efficacy

• Quantitative correlation analysis:

  • Create a standard curve of surface expression vs. current amplitude

  • Use this to determine if mutant receptors have normal channel properties but reduced surface expression, or normal surface expression but altered channel properties

  • This distinction is crucial for understanding disease mechanisms and developing therapies

The research described in search result employed these combined approaches by conducting mutagenesis of GLRA1, expressing constructs in HEK293 cells, and performing both protein analysis and electrophysiological recordings to understand how specific mutations affect receptor function.

What are the most common issues when working with GLRA1 antibodies and how can they be resolved?

For live cell staining, temperature control is critical—perform antibody incubation at 4°C to prevent internalization if surface labeling is desired . For fixation-sensitive epitopes, try alternative fixation methods or epitope retrieval techniques.

How should researchers interpret conflicting results when different GLRA1 antibodies show varying patterns of staining?

When facing conflicting results with different GLRA1 antibodies, researchers should follow this systematic approach to interpretation:

• Understand epitope differences:

  • Different antibodies target distinct regions of GLRA1 (N-terminal domain, internal regions, C-terminus)

  • Epitope accessibility may vary depending on receptor conformation, assembly state, or interactions with other proteins

  • Some epitopes may be masked in certain subcellular compartments

• Consider isoform specificity:

  • Some antibodies detect multiple GLRA subunits (e.g., both α1 and α2)

  • Others are highly specific for GLRA1

  • Verify which isoforms should be present in your tissue/cells

• Evaluate fixation and permeabilization effects:

  • Certain fixatives may denature some epitopes while preserving others

  • The degree of permeabilization affects antibody access to intracellular epitopes

  • Test multiple fixation protocols if discrepancies are observed

• Compare with complementary techniques:

  • Validate immunostaining patterns with mRNA expression data

  • Use in situ hybridization to confirm tissue distribution

  • Employ genetic models (knockout, knockdown) to confirm specificity

• Perform comprehensive blocking experiments:

  • Pre-adsorb each antibody with specific peptides as described in search results and

  • This can identify if cross-reactivity is causing discrepancies

• Evaluate technical quality:

  • Assess signal-to-noise ratio for each antibody

  • Consider sensitivity differences between antibodies

  • Higher quality data should generally be weighted more heavily

• Synthesize a coherent interpretation:

  • Different staining patterns may reflect biological reality (receptor heterogeneity)

  • Create a model that accounts for the most reliable data points

  • Explicitly acknowledge limitations and uncertainties

When possible, use genetic approaches to validate antibody findings, as demonstrated in search result where studies in Glra1+/+/Glrbeos/eos and Glra1spdot/spdot/Glrbeos/eos mice were used to validate antibody specificity and binding patterns.

What advanced methods can be used to quantify GLRA1 expression levels in tissue samples for comparative studies?

For precise quantification of GLRA1 expression in comparative studies, researchers can employ these advanced methodologies:

• Quantitative Western blotting:

  • Use fluorescently-labeled secondary antibodies for wider dynamic range

  • Include standard curves with recombinant protein

  • Normalize to multiple housekeeping proteins

  • Analyze with software such as STORM 860 fluoroimager as mentioned in search result

  • For membrane proteins, normalize to pan-cadherin rather than cytosolic proteins like GAPDH

• Multiplex immunofluorescence quantification:

  • Co-stain for GLRA1 and cell-type markers

  • Acquire high-resolution confocal z-stacks

  • Measure fluorescence intensity in defined cellular compartments

  • Use software like FIJI with specialized plugins as described in search result

  • Control for tissue thickness and antibody penetration

• Microarray binding assays:

  • Quantify binding intensities using imaging systems (e.g., Azure c400)

  • Detect with appropriate HRP-conjugated secondary antibodies

  • Analyze with specialized software like the "microarray profile" plugin for FIJI

  • This approach was successfully used in search result

• Receptor autoradiography:

  • Use radiolabeled ligands (e.g., [³H]strychnine) to label GlyRs

  • Quantify binding density across brain regions

  • Correlate with immunohistochemistry

• Mass spectrometry-based proteomics:

  • Employ targeted proteomics approaches (multiple reaction monitoring)

  • Use isotope-labeled peptide standards

  • Provides absolute quantification of GLRA1

  • Can distinguish between closely related isoforms

• ELISA-based quantification:

  • Develop sandwich ELISA with capture and detection antibodies

  • Generate standard curves with purified protein

  • This approach was mentioned in reference to glycine receptor extracellular domain preparation in search result

• Digital droplet PCR:

  • Complements protein analysis with absolute quantification of mRNA

  • Useful for validating antibody-based findings

  • Can detect transcript variants

Search result describes a particularly comprehensive approach combining microarray binding assays, cell-based assays, and tissue analysis with quantitative protein cluster analysis to quantify receptor levels in different experimental conditions.

How are GLRA1 antibodies being used to explore the role of glycine receptors in novel pathological conditions beyond hyperekplexia?

GLRA1 antibodies are expanding our understanding of glycine receptor involvement in several conditions:

• Autoimmune neurological disorders:

  • Research has identified GLRA1 as a target of autoantibodies in stiff-person syndrome (SPS) and progressive encephalomyelitis with rigidity and myoclonus (PERM)

  • Search result documented 52 antibody-positive patients with diverse clinical presentations

  • GLRA1 antibodies have also been implicated in some cases of focal epilepsy

  • These discoveries have shifted the paradigm from purely genetic to include autoimmune etiologies of glycinergic dysfunction

• Expanded spectrum of autoimmune targets:

  • Traditional focus was on antibodies targeting GlyRα subunits

  • Recent work identified GlyRβ as a novel target of autoantibodies in patients with SPS/PERM

  • Search result demonstrated that in contrast to GlyRα1-positive sera which alter glycine potency, antibodies against GlyRβ impair receptor efficacy

  • This finding suggests different pathophysiological mechanisms depending on the autoantibody target

• Investigation of neurodevelopmental disorders:

  • GLRA1 antibodies are being used to study glycinergic regulation of neuronal migration and synapse formation

  • Research is exploring potential links between glycine receptor dysfunction and conditions like autism spectrum disorders

• Pain processing abnormalities:

  • Growing evidence suggests glycine receptors contribute to inflammatory pain perception

  • GLRA1 antibodies are helping map changes in receptor expression in chronic pain models

• Sensory processing disorders:

  • GLRA1 is involved in modulation of auditory and visual pathways

  • Antibodies against GLRA1 are being used to investigate potential roles in sensory hypersensitivity disorders

The approach described in search result , using multiple techniques including cell-based assays, tissue immunohistochemistry, preadsorption approaches, and functional studies, represents a comprehensive framework for investigating glycine receptor involvement in various neurological conditions.

What methodological advances are improving the specificity and sensitivity of GLRA1 antibody-based detection systems?

Recent methodological advances have significantly enhanced GLRA1 antibody detection systems:

• Enhanced cell-based assays:

  • Transfection of HEK293 cells with GlyRα1 tagged with enhanced green fluorescent protein

  • Allows simultaneous visualization of both the receptor and bound antibodies

  • Enables live cell imaging of receptor dynamics

  • This approach has been successful in detecting patient autoantibodies as described in search result

• Multicolor immunofluorescence and spectral unmixing:

  • Simultaneous detection of multiple glycine receptor subunits

  • Distinguishes between closely related epitopes

  • Reduces false positives from autofluorescence

  • Examples include co-staining with antibodies against myc-tagged GlyRβ, gephyrin, synapsin, and pan-α-GlyR

• Single-molecule localization microscopy:

  • Super-resolution techniques (STORM, PALM) achieve nanometer precision

  • Enables visualization of individual glycine receptor clusters

  • Provides quantitative data on receptor density and organization

• Proximity ligation assays:

  • Detects protein-protein interactions in situ

  • Can identify glycine receptor associations with scaffolding proteins

  • Increases specificity by requiring two antibodies to be in close proximity

• Automated high-content imaging:

  • Machine learning algorithms for unbiased analysis

  • Reduces inter-observer variability

  • Enables large-scale screening applications

• Microfluidic antibody screening platforms:

  • Rapid testing of multiple antibodies simultaneously

  • Reduces sample requirements

  • Increases throughput for diagnostic applications

  • Similar to the microarray binding assay described in search result

• Recombinant antibody technologies:

  • Creation of single-chain variable fragments (scFvs)

  • Improved penetration into tissue sections

  • Reduced background from secondary antibody cross-reactivity

These methodological advances have collectively improved both sensitivity and specificity, allowing for more precise characterization of glycine receptor expression and function in various neurological conditions.

How can researchers effectively combine GLRA1 antibodies with CRISPR-Cas9 genome editing to develop new models of glycine receptor dysfunction?

Integrating GLRA1 antibodies with CRISPR-Cas9 genome editing offers powerful approaches for glycine receptor research:

• Validation of antibody specificity using knockout models:

  • Generate GLRA1 knockout cell lines using CRISPR-Cas9

  • Confirm complete absence of antibody signal in knockout cells

  • Provides definitive control for antibody specificity

  • Particularly valuable when validating novel antibodies

• Creation of tagged endogenous receptors:

  • Use CRISPR-Cas9 knock-in strategies to add epitope tags (FLAG, HA, myc) to endogenous GLRA1

  • Allows detection with highly specific tag antibodies

  • Maintains physiological expression levels and regulatory elements

  • Similar to the myc-tagged constructs described in search result

• Generating disease-relevant mutations:

  • Introduce hyperekplexia-associated mutations (e.g., spd^ot, T309R) into cellular or animal models

  • Use GLRA1 antibodies to assess expression patterns and trafficking

  • Compare with previous findings using transfected mutants

  • Search result provides a framework for analyzing such mutations

• Exploring structure-function relationships:

  • Create domain swaps or specific mutations as described in search result

  • Use CRISPR-Cas9 to introduce these changes to endogenous genes

  • Apply GLRA1 antibodies to study trafficking and localization

• Development of reporter systems:

  • Create knock-in fluorescent reporter fusions (GLRA1-GFP)

  • Combine with antibodies against interacting proteins

  • Enables live imaging of receptor dynamics in physiological contexts

• Differential labeling of surface and internal pools:

  • Use CRISPR to introduce distinct tags on extracellular and intracellular domains

  • Apply non-permeabilizing and permeabilizing conditions with different antibodies

  • Quantify surface/internal ratios with high precision

• High-throughput phenotypic screening:

  • Generate CRISPR libraries targeting GLRA1 regulatory elements

  • Use antibody-based detection for screening altered expression

  • Identify novel regulatory mechanisms

The combination of precise genome editing with specific antibody detection provides a powerful platform for developing new models of glycine receptor dysfunction that more accurately reflect human disease conditions than previous overexpression systems.